Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.33)
# 344
Out of 5,114 analysts
90
Total ratings
55.38%
Success rate
18.21%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $750 → $875 | $749.44 | +16.75% | 6 | Jan 22, 2026 | |
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $25.07 | +59.55% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $20.88 | +163.41% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $29.29 | +19.49% | 1 | Nov 24, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Outperform | $25 | $10.76 | +132.34% | 1 | Nov 20, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $40 | $30.94 | +29.28% | 1 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $65.60 | +21.95% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $7.78 | +54.24% | 1 | Sep 3, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $15.40 | +120.78% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $41.76 | +31.70% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $50 → $32 | $46.86 | -31.71% | 6 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $137.96 | +34.10% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $79.10 | -36.79% | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $28.78 | +73.73% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $116.77 | +7.05% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $56.99 | +84.24% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $68.26 | +24.52% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $24.27 | +262.59% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $176.18 | +56.66% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $4.60 | +660.87% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $342.94 | -32.35% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $101.08 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $139.55 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $34.88 | -39.79% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $6.43 | +257.70% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $15.48 | +1,514.99% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.44 | +594.44% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $16.85 | - | 5 | Feb 14, 2018 |
Regeneron Pharmaceuticals
Jan 22, 2026
Maintains: Outperform
Price Target: $750 → $875
Current: $749.44
Upside: +16.75%
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $25.07
Upside: +59.55%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $20.88
Upside: +163.41%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $29.29
Upside: +19.49%
ORIC Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $10.76
Upside: +132.34%
Upstream Bio
Nov 18, 2025
Initiates: Outperform
Price Target: $40
Current: $30.94
Upside: +29.28%
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $65.60
Upside: +21.95%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $7.78
Upside: +54.24%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $15.40
Upside: +120.78%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $41.76
Upside: +31.70%
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $46.86
Upside: -31.71%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $137.96
Upside: +34.10%
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $79.10
Upside: -36.79%
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $28.78
Upside: +73.73%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $116.77
Upside: +7.05%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $56.99
Upside: +84.24%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $68.26
Upside: +24.52%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $24.27
Upside: +262.59%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $176.18
Upside: +56.66%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $4.60
Upside: +660.87%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $342.94
Upside: -32.35%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $101.08
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $139.55
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $34.88
Upside: -39.79%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $6.43
Upside: +257.70%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $15.48
Upside: +1,514.99%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.44
Upside: +594.44%
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $16.85
Upside: -